News Agios shares slump on sickle cell disease data Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.
Events Partner Content 2nd Gene Therapy for Blood Disorders Gene Therapy for Blood Disorders Digital Summit
News Celgene files potential blockbuster luspatercept Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.
Oncology Sponsored The Compound Effect: Real-World Evidence for the Impact of C... In a new report, Medscape Medical Affairs explores the question of whether a coordinated programme drives more real-world behaviour change.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.